Drug
Regn475
Regn475: highest development phase Phase 1/2, developed by Regeneron. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Regeneron
Trials
| Drug | Phase | Indication |
|---|---|---|
| REGN475 NCT00944892 | Phase 1/2 | Osteoarthritis of the Knee |
Latest
No recent events.
Follow Regn475 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.